Search Results

California-based biotech Nuvig Therapeutics scooped up $161 million from the investment arms of Sanofi, Bayer, Novo Holdings, BMS and others for its Fc fragment immunomodulator aimed at improving autoimmune dysregulation.

Tendonitis Market Outlook 2025-2035:

Juvena Therapeutics today announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation to the company’s flagship candidate, JUV-161. JUV-161 is an investigational therapeutic for the treatment of Myotonic Dystrophy Type 1 (DM1), a rare, multi-systemic, autosomal dominant inherited disease and the most common form of adult muscular dystrophy.

IDEAYA Biosciences, Inc. announced that it has entered into a clinical trial collaboration and supply agreement with Merck to evaluate IDE161, the company’s investigational, potential first-in-class, small molecule poly glycohydrolase, or PARG, inhibitor, in combination with KEYTRUDA® Merck’s anti-PD-1 therapy, in patients with microsatellite instability-, or MSI-, high and microsatellite stable, or MSS, endometrial cancer, in a Phase 1 clinical trial.

Radiopharm Theranostics is pleased to announce an expanded agreement with TerThera to supply the Company with Terbium-161.